全文获取类型
收费全文 | 146384篇 |
免费 | 7405篇 |
国内免费 | 1432篇 |
专业分类
耳鼻咽喉 | 1843篇 |
儿科学 | 6633篇 |
妇产科学 | 2757篇 |
基础医学 | 12876篇 |
口腔科学 | 4384篇 |
临床医学 | 11396篇 |
内科学 | 28333篇 |
皮肤病学 | 3823篇 |
神经病学 | 9026篇 |
特种医学 | 6129篇 |
外国民族医学 | 5篇 |
外科学 | 26117篇 |
综合类 | 8263篇 |
现状与发展 | 3篇 |
预防医学 | 9508篇 |
眼科学 | 2483篇 |
药学 | 11986篇 |
5篇 | |
中国医学 | 3467篇 |
肿瘤学 | 6184篇 |
出版年
2023年 | 3729篇 |
2022年 | 4762篇 |
2021年 | 6632篇 |
2020年 | 4907篇 |
2019年 | 12545篇 |
2018年 | 9736篇 |
2017年 | 5033篇 |
2016年 | 2215篇 |
2015年 | 3098篇 |
2014年 | 5255篇 |
2013年 | 3608篇 |
2012年 | 2876篇 |
2011年 | 6344篇 |
2010年 | 3327篇 |
2009年 | 4211篇 |
2008年 | 3459篇 |
2007年 | 3850篇 |
2006年 | 3324篇 |
2005年 | 3354篇 |
2004年 | 2405篇 |
2003年 | 2001篇 |
2002年 | 2399篇 |
2001年 | 2616篇 |
2000年 | 3567篇 |
1999年 | 3776篇 |
1998年 | 3550篇 |
1997年 | 2482篇 |
1996年 | 1761篇 |
1995年 | 1300篇 |
1994年 | 1294篇 |
1993年 | 890篇 |
1992年 | 932篇 |
1991年 | 792篇 |
1990年 | 776篇 |
1989年 | 575篇 |
1988年 | 595篇 |
1987年 | 452篇 |
1985年 | 2994篇 |
1984年 | 4309篇 |
1983年 | 3066篇 |
1982年 | 3010篇 |
1981年 | 2801篇 |
1980年 | 2492篇 |
1979年 | 2288篇 |
1978年 | 1858篇 |
1977年 | 1620篇 |
1976年 | 1735篇 |
1975年 | 1470篇 |
1974年 | 1316篇 |
1973年 | 1220篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
91.
92.
93.
94.
95.
96.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献
97.
98.
《Vaccine》2021,39(26):3498-3508
Adenovirus infections are a major cause of epidemic keratoconjunctivitis (EKC), which can lead to corneal subepithelial infiltrates and multifocal corneal opacity. In the current study, we investigated the use of an E1/E3-deleted adenovirus serotype 5 (Ad5) vector as a vaccine administered intramuscularly (IM) or intranasally (IN) against subsequent challenges with a luciferase-expressing Ad5 (Ad5-Luci) vector via eyedrop. We evaluated the adaptive immune response to Ad5 vector vaccination and confirmed a robust polyfunctional CD8 T cell response in splenic cells. Neutralizing Ad5 antibodies were also measured in the sera of vaccinated mice as well as Ad5 antibody in the eye wash solutions. Upon challenge with Ad5-Luci vector 8 weeks post the primary immunization, transduction was significantly reduced by > 70% in the vaccinated mice, which was slightly better in IM- vs. that in IN-vaccinated animals. Resistance to subsequent challenge was observed 10 months post primary IM vaccination, with sustained reduction up to 60% in the Ad5-Luci vector transduction. Passive immunization of naive mice with antisera from IM to vaccinated mice subsequently challenged with the Ad5-Luci vector resulted in approximately 40% loss in transduction efficiency. Furthermore, the mice that received IM immunization with or without CD8 T cell depletion showed > 40% and 70% reductions, respectively, in Ad8 genomic copies after Ad8 topical challenge. We conclude that Ad-vector vaccination successfully induced an adaptive immune response that prevented subsequent Ad transduction in the cornea and conjunctiva-associated tissues in a mouse model of adenovirus keratoconjunctivitis, and that both cellular and humoral immunity play an important role in preventing Ad transduction. 相似文献
99.
《Ophthalmology》2020,127(11):1498-1506
100.
《Diagnostic and interventional imaging》2021,102(10):641-648
PurposeTo evaluate the potential differences in non-target embolization and vessel microsphere filling of a reflux-control microcatheter (RCM) compared to a standard end-hole microcatheter (SEHM) in a swine model.Materials and methodsRadiopaque microspheres were injected with both RCM and SEHM (2.4-Fr and 2.7-Fr) in the kidneys of a preclinical swine model. Transarterial renal embolization procedures with RCM or SEHM were performed in both kidneys of 14 pigs. Renal arteries were selectively embolized with an automated injection protocol of radio-opaque microspheres. Ex-vivo X-ray microtomography images of the kidneys were utilized to evaluate the embolization by quantification of the deposition of injected microspheres in the target vs. the non-target area of injection. X-ray microtomography images were blindly analyzed by five interventional radiologists. The degree of vessel filling and the non-target embolization were quantified using a scale from 1 to 5 for each parameter. An analysis of variance was used to compare the paired scores.ResultsTotal volumes of radio-opaque microspheres injected were similar for RCM (11.5 ± 3.6 [SD] mL; range: 6–17 mL) and SEHM (10.6 ± 5.2 [SD] mL; range: 4–19 mL) (P = 0.38). The voxels enhanced ratio in the target (T) vs. non-target (NT) areas was greater with RCM (T = 98.3% vs. NT = 1.7%) than with SEHM (T = 89% vs. NT = 11%) but the difference was not significant (P = 0.30). The total score blindly given by the five interventional radiologists was significantly different between RCM (12.3 ± 2.1 [SD]; range: 6–15) and the standard catheter (11.3 ± 2.5 [SD]; range: 4–15) (P = 0.0073), with a significant decrease of non-target embolization for RCM (3.8 ± 1.3 [SD]; range: 3.5–4.2) compared to SEHM (3.2 ± 1.5 [SD]; range: 2.9–3.5) (P = 0.014).ConclusionIn an animal model, RCM microcatheters reduce the risk of non-target embolization from 11% to 1.7%, increasing the delivery of microspheres of 98% to the target vessels, compared to SEHM microcatheters. 相似文献